Glycogen storage disease type II – Diagnostics – Overview of Information and Clinical Research

Glycogen storage disease type II, also called Pompe disease, is a rare inherited condition that affects how the body breaks down and uses stored energy. Understanding how this disease is diagnosed is crucial because early detection can significantly improve outcomes, especially in infants and young children who may develop severe symptoms.

Introduction: Who Should Undergo Diagnostics

Certain groups of people should consider diagnostic testing for glycogen storage disease type II. Newborns in many regions now receive screening for this condition as part of routine newborn screening programs, which allows for very early detection before symptoms appear.^[1] This early identification is particularly important because treatment works best when started as soon as possible.

Infants who show concerning signs such as severe muscle weakness, an unusually floppy appearance (what doctors call hypotonia, or low muscle tone), difficulty feeding, breathing problems, or an enlarged heart should be evaluated for Pompe disease. These symptoms typically appear within the first few months of life in the more severe form of the condition.^[2] Parents may notice that their baby cannot hold their head up, has trouble rolling over, or does not reach other typical developmental milestones expected for their age.

Children and adults should seek diagnostic testing if they experience progressive muscle weakness, especially in the large muscles of the legs, trunk, and arms. Difficulty climbing stairs, increasing trouble walking, or breathing difficulties during sleep can be early warning signs of late-onset Pompe disease.^[3] Some people may also experience muscle pain affecting large areas of the body.

Family members of someone diagnosed with Pompe disease should also consider testing, particularly if they are planning to have children. Because this condition follows an autosomal recessive pattern of inheritance (meaning both parents must carry the genetic change for a child to develop the disease), knowing carrier status helps families make informed decisions.^[1]

⚠️ Important

When Pompe disease is detected early through newborn screening and treatment begins promptly, many babies with this condition can live longer lives with improved growth and development. Further testing is always needed after an initial screening test comes back out of range, as screening tests alone cannot confirm a diagnosis.

Classic Diagnostic Methods

The diagnosis of glycogen storage disease type II relies on several different testing approaches that work together to confirm whether someone has the condition. The most definitive way to diagnose Pompe disease is by measuring the activity level of a specific enzyme in the body.

Enzyme Activity Testing

The primary diagnostic test involves measuring the activity of an enzyme called acid alpha-glucosidase (also known as GAA or acid maltase). This enzyme normally works inside small compartments within cells called lysosomes, where it breaks down glycogen into simpler sugars the body can use for energy. When this enzyme is missing or not working properly, glycogen builds up in cells and causes damage, particularly to muscle tissue.^[4]

This enzyme activity can be measured in several types of samples. The most common approach uses a blood sample, specifically looking at white blood cells. Other options include testing cells from a skin biopsy (called fibroblasts) or muscle tissue taken during a muscle biopsy. The choice of which sample to use often depends on what facilities and testing capabilities are available at the diagnostic laboratory.^[5] Each method has its advantages, but all aim to answer the same question: is the acid alpha-glucosidase enzyme working properly?

For newborn screening, laboratories look for low levels of GAA enzyme activity in the small blood samples collected from a baby’s heel shortly after birth. When the screening shows low enzyme levels, it signals that the baby could have Pompe disease, though additional confirmatory testing is always required.^[6]

Biochemical Investigations

Beyond enzyme testing, doctors often order a series of blood tests to look for abnormalities that commonly occur in Pompe disease. One key finding is elevated levels of creatine kinase, an enzyme that leaks out of damaged muscle cells. In people with Pompe disease, creatine kinase levels in the blood are typically increased about ten times higher than normal.^[5] However, it is worth noting that in late-onset forms of the disease, creatine kinase levels may sometimes be normal, which is why this test alone cannot rule out the condition.

Other blood tests may show lesser elevations in related enzymes such as aldolase, aspartate transaminase, alanine transaminase, and lactic dehydrogenase. These markers help doctors understand the extent of muscle damage and monitor disease progression.^[5]

Genetic Testing

Once enzyme testing suggests Pompe disease, genetic testing provides confirmation by identifying the specific mutations in the GAA gene that cause the condition. This gene provides instructions for making the acid alpha-glucosidase enzyme. When mutations prevent this enzyme from being made or from working correctly, glycogen accumulates in cells throughout the body.^[7]

Genetic testing is particularly useful for several reasons. It can confirm the diagnosis when enzyme results are unclear, help determine what type of Pompe disease someone has (infantile-onset or late-onset), and identify family members who may be carriers of the genetic mutations. The test typically uses a blood sample to analyze white blood cells and look for mutations in both copies of the GAA gene.^[8]

Cross-Reactive Immunological Material (CRIM) Status

For patients with infantile-onset Pompe disease, an additional test determines something called CRIM status. This test reveals whether a patient produces any GAA protein at all, even if it does not work properly. Patients who produce no GAA protein are called CRIM-negative, while those who produce some protein (even if it is non-functional) are CRIM-positive.^[2]

This distinction is clinically important because CRIM-negative patients may develop a strong immune response against enzyme replacement therapy, viewing the replacement enzyme as a foreign substance. Understanding CRIM status helps doctors plan the most effective treatment approach and may indicate whether additional immune-modulating therapies will be needed.^[1]

Imaging Studies

Several imaging tests help doctors evaluate the effects of Pompe disease on the body. A chest X-ray can reveal an enlarged heart, which is a characteristic finding in infantile-onset Pompe disease. The heart enlarges because glycogen accumulates in the heart muscle, causing it to thicken and expand.^[5]

An echocardiogram, which uses sound waves to create pictures of the heart, provides more detailed information about heart size and function. This test can show hypertrophic cardiomyopathy (thickening of the heart muscle) and help doctors assess how well the heart is pumping blood. An electrocardiogram (ECG) records the electrical activity of the heart and may reveal non-specific abnormalities in how electrical signals travel through the heart muscle.^[5]

For patients with muscle weakness, doctors may use electromyography (EMG), a test that measures the electrical activity of muscles. This can help distinguish Pompe disease from other conditions that cause muscle weakness.^[4]

Tissue Biopsy

In some cases, doctors may perform a muscle biopsy, which involves taking a small sample of muscle tissue for examination under a microscope. The tissue sample can reveal large vacuoles (empty-looking spaces) filled with glycogen inside muscle cells, a hallmark sign of Pompe disease. This procedure is less commonly needed now that enzyme and genetic testing are widely available, but it can provide valuable information in certain situations.^[4]

Distinguishing Pompe Disease from Other Conditions

Because muscle weakness and heart problems can occur in many different conditions, doctors must carefully distinguish Pompe disease from other disorders. Conditions that may appear similar include other types of glycogen storage diseases, muscular dystrophies, and various forms of cardiomyopathy. The combination of low enzyme activity, genetic mutations in the GAA gene, and characteristic clinical features helps doctors make the correct diagnosis.^[1]

For late-onset Pompe disease, the diagnostic process may take longer because symptoms develop gradually and can be mistaken for other conditions affecting muscles or breathing. Some patients experience symptoms for years before receiving the correct diagnosis. This makes awareness among healthcare providers crucial for timely identification of the disease.^[3]

⚠️ Important

A positive newborn screening result does not automatically mean a baby has Pompe disease. These screening tests are designed to be very sensitive, which means they sometimes flag babies who do not actually have the condition. All positive screening results must be followed up with confirmatory testing, such as enzyme activity measurement and genetic testing, before a diagnosis can be made.

Diagnostics for Clinical Trial Qualification

When patients with Pompe disease are being considered for enrollment in clinical trials, they typically undergo additional diagnostic tests beyond those used for standard diagnosis. Clinical trials are research studies that test new treatments or ways of managing the disease, and they require careful documentation of each patient’s condition to ensure accurate measurement of treatment effects.

Baseline Enzyme Activity Assessment

Before entering a clinical trial, researchers need to establish baseline measurements of GAA enzyme activity. This involves the same biochemical assay used for diagnosis but is repeated and carefully documented to provide a reference point for comparing any changes that might occur during the trial. These measurements help researchers understand the severity of enzyme deficiency and track whether experimental treatments have any effect on enzyme levels.^[1]

Genetic Characterization

Clinical trials often require detailed genetic testing to identify the exact mutations present in each participant. Different mutations in the GAA gene can lead to different levels of enzyme deficiency and different rates of disease progression. Some trials may specifically enroll patients with certain types of mutations, while others may need to ensure a diverse range of genetic variants is represented.^[8] This genetic information also helps researchers understand which types of patients might benefit most from a particular treatment approach.

Functional Assessments

To measure how well a treatment works, clinical trials need objective ways to assess patient function. For late-onset Pompe disease trials, this commonly includes a six-minute walk test, where patients walk as far as they can in six minutes while researchers measure the distance. Changes in walking distance over time can indicate whether muscle strength is improving, staying stable, or declining.^[13]

Respiratory function testing is another critical assessment, particularly because breathing muscle weakness is a major concern in Pompe disease. Tests measure lung capacity, how much air a person can forcefully exhale, and how well the diaphragm (the main breathing muscle) is working. These measurements are tracked throughout the trial to see if treatments help preserve or improve breathing function.^[1]

Cardiac Monitoring for Infantile-Onset Trials

For clinical trials involving infants with Pompe disease, careful monitoring of heart size and function is essential. Regular echocardiograms track changes in the thickness of the heart muscle and how effectively the heart pumps blood. Electrocardiograms monitor the heart’s electrical activity. These tests are performed at regular intervals throughout the trial to document whether treatment prevents or reverses heart enlargement.^[10]

Quality of Life Measurements

Beyond physical measurements, clinical trials often include questionnaires that assess quality of life, daily functioning, and overall health status. These tools help researchers understand whether treatments improve not just laboratory values or test results, but also how patients actually feel and function in their daily lives. For children, these assessments may evaluate developmental milestones and the ability to perform age-appropriate activities.^[10]

Biomarker Studies

Some clinical trials collect additional blood or urine samples to study various biomarkers (measurable indicators of the disease). These might include markers of muscle breakdown, inflammatory molecules, or other substances that reflect disease activity. While not used for routine diagnosis, these biomarkers help researchers understand how the disease affects the body and whether treatments are having the desired biological effects.^[14]

Imaging for Disease Monitoring

Advanced imaging techniques, including magnetic resonance imaging (MRI) of muscles, may be used in clinical trials to directly visualize glycogen accumulation in tissues and track changes over time. These specialized imaging studies provide detailed information about which muscles are most affected and whether treatment reduces glycogen buildup.^[10]

Regular Safety Monitoring

All clinical trial participants undergo regular safety monitoring, including routine blood tests to check liver function, kidney function, and blood cell counts. For trials testing enzyme replacement therapies or other treatments that might trigger immune responses, special tests monitor for antibody formation against the treatment. This is particularly important for CRIM-negative patients, who are at higher risk of developing antibodies that could reduce treatment effectiveness.^[2]

The comprehensive diagnostic evaluation required for clinical trial participation ensures that researchers can accurately measure treatment effects and that participants are monitored closely for both benefits and potential risks. While these additional tests may seem extensive, they are crucial for developing new and better treatments for Pompe disease.

Prognosis and Survival Rate

Prognosis

The outlook for individuals with glycogen storage disease type II varies significantly depending on the form of the disease and when treatment begins. For infantile-onset Pompe disease, the prognosis was historically very poor. Before effective treatments became available, the median age at death was approximately 8.7 months, with most infants dying from cardiorespiratory failure before their first birthday. However, this outcome has changed dramatically since enzyme replacement therapy became available, especially when treatment starts early after detection through newborn screening.^[2]

With early treatment initiation, many babies with infantile-onset Pompe disease now survive beyond early childhood and experience improved growth and development. The most favorable outcomes occur when treatment begins before significant heart enlargement has occurred and before respiratory complications develop. Early detection through newborn screening programs has been crucial in improving outcomes for these patients.^[1]

Late-onset Pompe disease generally has a more gradual progression. Without treatment, the disease slowly but progressively worsens over years, with increasing muscle weakness and eventual respiratory insufficiency. The heart is rarely affected in late-onset forms, which improves the overall prognosis compared to infantile-onset disease. The rate of progression can vary considerably from person to person, with some individuals experiencing relatively mild symptoms that progress slowly over decades, while others face more rapid deterioration.^[3]

Several factors influence prognosis in Pompe disease. The amount of residual enzyme activity plays a major role—individuals with some remaining enzyme function typically have milder disease and slower progression. CRIM status affects how well patients respond to enzyme replacement therapy, with CRIM-negative patients at higher risk of developing antibodies that reduce treatment effectiveness. The age at which treatment begins is also critical, as starting therapy before irreversible muscle damage occurs leads to better outcomes.^[1]

Survival Rate

Survival rates for Pompe disease have improved substantially with the advent of enzyme replacement therapy. For infantile-onset Pompe disease without treatment, survival beyond the first year of life was extremely rare. Historical data showed that most affected infants died before 12 months of age due to heart failure and respiratory complications.^[5]

With enzyme replacement therapy, survival has dramatically improved. Studies have shown that early treatment intervention, particularly when started before significant symptoms develop through newborn screening programs, has led to prolonged survival well beyond infancy. Many treated children now survive past early childhood, though long-term survival data is still being collected as the treatment has only been available since the mid-2000s.^[11]

For late-onset Pompe disease, survival is generally measured in years to decades rather than months. Without treatment, respiratory failure from weakness of the diaphragm and other breathing muscles is the most common cause of death. The progression can vary widely, with some individuals living relatively normal lifespans with good disease management, while others experience more rapid decline.^[3]

Treatment with enzyme replacement therapy has been shown to slow disease progression in late-onset Pompe disease, helping to maintain muscle strength and respiratory function. While the treatment does not cure the disease, it can significantly extend life expectancy and improve quality of life when initiated before severe, irreversible muscle damage occurs. Ongoing monitoring and comprehensive care, including respiratory support when needed, are essential components of maintaining the best possible outcomes for individuals with this condition.^[11]

#1 Clinical Trials Search in Europe

Glycogen storage disease type II – Diagnostics

Introduction: Who Should Undergo Diagnostics